|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for CASP9 |
 Gene summary |
| Basic gene Info. | Gene symbol | CASP9 |
| Gene name | caspase 9, apoptosis-related cysteine peptidase | |
| Synonyms | APAF-3|APAF3|ICE-LAP6|MCH6|PPP1R56 | |
| Cytomap | UCSC genome browser: 1p36.21 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001229.4, NM_001278054.1,NM_032996.3,NR_102732.1,NR_102733.1, | |
| Description | ICE-like apoptotic protease 6apoptotic protease MCH-6apoptotic protease activating factor 3caspase-9protein phosphatase 1, regulatory subunit 56 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 602234 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000132906 | ||
| HPRD : 03756 | ||
| Vega : OTTHUMG00000002256 | ||
| Protein | UniProt: P55211 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CASP9 | |
| BioGPS: 842 | ||
| Pathway | NCI Pathway Interaction Database: CASP9 | |
| KEGG: CASP9 | ||
| REACTOME: CASP9 | ||
| Pathway Commons: CASP9 | ||
| Context | iHOP: CASP9 | |
| ligand binding site mutation search in PubMed: CASP9 | ||
| UCL Cancer Institute: CASP9 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0006974 | cellular response to DNA damage stimulus | 15657060 | GO:0034644 | cellular response to UV | 15657060 | GO:0042770 | signal transduction in response to DNA damage | 15657060 |
| Top |
| Ligand binding site mutations for CASP9 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | R180 | R180H | STAD | 1 | R180 | R180H | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for CASP9 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | R180 | R180H | -1.2926799 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for CASP9 from PDB |
| Top |
| Differential gene expression and gene-gene network for CASP9 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for CASP9 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0033578 | Prostatic Neoplasms | 3 | Biomarker, GeneticVariation |
| umls:C0007786 | Brain Ischemia | 1 | Biomarker |
| umls:C0013604 | Edema | 1 | Biomarker |
| umls:C0007787 | Ischemic Attack, Transient | 1 | Biomarker |
| umls:C0027055 | Myocardial Reperfusion Injury | 1 | Biomarker |
| umls:C0027765 | Nervous System Diseases | 1 | Biomarker |
| umls:C0031117 | Peripheral Nervous System Diseases | 1 | Biomarker |
| umls:C0035305 | Retinal Detachment | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for CASP9 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of CASP9 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of CASP9 |
| Multiple alignments for P55211 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |